than with 50 mg in groups of patients.
Consequently, in patients with inadequate blood pressure response to losartan 50 mg, a common recommendation from the manufacturer has been to add hydrochlorothiazide rather than to increase the dose.
In the conclusion to our paper, we state that 'Candesartan cilexetil 16 mg is significantly more effective than losartan 50 mg once daily, 24 h after dose administration'. This is a valid interpretation of our data, and we have not attempted to extend this to involve losartan 100 mg.
The second item of concern according to Merck is the blinding method in the study, that is the possibility that encapsulation of losartan would have altered the original product characteristics. To exclude this the standard procedure in clinical trials is to perform in vitro dissolution tests of the original and encapsulated products (an accepted procedure by regulatory authorities regarding immediate-release compounds), and such testing in our study showed no effect of encapsulation on the dissolution profile of losartan.
Furthermore, the bioavailability of original losartan and losartan encapsulated by the method used in our study has been compared in healthy volunteers. The findings showed virtually identical plasma profiles for the encapsulated and non-encapsulated product, both of plasma concentrations of losartan and EXP-3174 (the active metabolite of losartan). For losartan and EXP-3174 the estimated ratios of the true treatment medians of area under the curve and maximal plasma concentrations of both formulations were all close to 1 and the 90% CI's were within the limits established for bioequivalence (0.80-1.25). It can therefore be concluded that encapsulation of commerically available losartan tablets by the method used in our study does not affect its bioavailability.
In summary, we are confident that the conclusions drawn in our paper is in accordance with the study design and results, and are likely to represent a clinical reality. 
A new cause of arterial hypertension: postmenopausal breast cancer in complete clinical remission
This is a concise communication of some clinical data to support the observation of frequent mild arterial hypertension in postmenopausal women with breast cancer in complete clinical remission of over 5 years duration. In a pilot study of cases and controls in which we measured the blood pressure (BP) of 83 postmenopausal women with histologically confirmed breast cancer who had been in complete clinical remission over 5 years, were recruited by consecutive sampling, compared with 70 normal Mean diastolic BP in the patients in complete remission was 98 mm Hg (95% CI 94 -104); in the controls 78 mm Hg (95% CI 74 -82); and in the cases of clinical relapse it was 84 mm Hg (95% CI 78-90). The difference between cases of complete clinical remission and normal controls and patients in clinical relapse was significant (P Ͻ 0.001). There was not a significant correlation between BP and BMI or between BP and the duration of the disease-free interval (Table 1) .
Mild arterial hypertension, associated with complete clinical remission, is independent of BMI and the duration of the diseasefree interval; this is possibly related to an increase in ACE activity and its reaction against the tumour.
2,3 Either way it is a sign of a good prognosis in breast cancer.
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